GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial

A trial of 108 adults with obesity seeking treatment for alcohol use finds a once-weekly semaglutide injection reduced heavy drinking days in the past 30 days by an average of roughly 12 days, 50% higher than the eight-day reduction seen in the placebo group. The study is published in The Lancet.